Financiado en parte por Takeda Pharmaceuticals U.S.A.
Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases
Winter RW, Collins E, Cao B, Carrellas M, Crowell AM, Korzenik JR
Alimentary pharmacology & therapeutics · 63 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Takeda Pharmaceuticals U.S.A.
- Gobierno
- National Institutes of Health
- Gobierno
- National Institute of Diabetes and Digestive and Kidney Diseases
- Gobierno
- NIDDK NIH HHS
- Subvenciones
- National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK007533); National Institutes of Health (T32 DK007533-29)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2017-01-10 · Aliment Pharmacol Ther · vol. 45 · número 5 · págs. 653–659
- Editorial
- Wiley
- Citado
- 74 citas · más que el 97% de estudios similares · 6.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 19 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Vitamin D Research Studies · Inflammatory Bowel Disease · Vitamin C and Antioxidants Research
- Palabras clave
- Medicine, Inflammatory Bowel Diseases, Internal medicine, Gastroenterology, Odds ratio, Inflammatory bowel disease, Tumor necrosis factor alpha, Necrosis, Odds, Risk factor, Tumor necrosis factor α, Logistic regression, Disease
- MeSH
- humans, inflammatory bowel diseases, vitamin d, tumor necrosis factor-alpha, logistic models, retrospective studies, adult, middle aged, female, male, young adult, adalimumab, infliximab
6 autores
- Rachel W. Winter🇺🇸 · autor de correspondenciaBrigham and Women's Hospital
- Emily Collins🇺🇸Brigham and Women's Hospital
- Bangping Cao🇺🇸Brigham and Women's Hospital
- Madeline Carrellas🇺🇸Brigham and Women's Hospital
- Anne Marie Crowell🇺🇸Brigham and Women's Hospital
- Joshua R. Korzenik🇺🇸Brigham and Women's Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Vitamin D has been linked to disease activity among patients with inflammatory bowel diseases (IBD). Prior investigation has also suggested that vitamin D levels may affect duration of therapy with anti-tumour necrosis factor-α (anti-TNF-α) medications among patients with IBD.
Aim
To evaluate the relationship between vitamin D levels and odds of reaching remission while on an anti-TNF-α medication.
Methods
A total of 521 IBD patients enrolled in the Brigham and Women's IBD Centre database were eligible for inclusion. Patients treated with anti-TNF-α therapy who had vitamin D levels drawn within 6 months prior or 2 weeks after initiation of anti-TNF-α medication and who had reported remission status at 3 months were included. A logistic regression model adjusting for age, gender, IBD diagnosis, anti-TNF-α medication (infliximab vs. adalimumab) and first or subsequent anti-TNF-α medication was used to identify the effect of vitamin D level on initial response to anti-TNF-α therapy.
Results
A total of 173 patients were included in the final analysis. On logistic regression, patients with normal vitamin D levels n = 122 at the time of anti-TNF-α medication initiation had a 2.64 increased odds of remission at 3 months compared to patients with low vitamin D levels n = 51 when controlling for age, gender, diagnosis, type of anti-TNF-α medication and first or subsequent anti-TNF-α medication (OR = 2.64, 95% CI = 1.31-5.32, P = 0.0067).
Conclusions
These findings suggest that vitamin D levels may influence initial response to anti-TNF-α medication and that low vitamin D levels may pre-dispose patients to decreased odds of remission.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.